CN113908212A - Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof - Google Patents
Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof Download PDFInfo
- Publication number
- CN113908212A CN113908212A CN202111455567.4A CN202111455567A CN113908212A CN 113908212 A CN113908212 A CN 113908212A CN 202111455567 A CN202111455567 A CN 202111455567A CN 113908212 A CN113908212 A CN 113908212A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- preparation
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims abstract description 35
- 230000006378 damage Effects 0.000 title claims abstract description 31
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 30
- 208000014674 injury Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 210000004347 intestinal mucosa Anatomy 0.000 title claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 16
- 241000301400 Trogopterus Species 0.000 claims abstract description 16
- 210000003608 fece Anatomy 0.000 claims abstract description 16
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 15
- 241000951473 Schizonepeta Species 0.000 claims abstract description 15
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 15
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 15
- 241000219784 Sophora Species 0.000 claims abstract description 14
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims description 43
- 241000219991 Lythraceae Species 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 abstract description 13
- 210000004877 mucosa Anatomy 0.000 abstract description 8
- 230000002411 adverse Effects 0.000 abstract description 5
- 208000008469 Peptic Ulcer Diseases 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 abstract description 3
- 206010018001 Gastrointestinal perforation Diseases 0.000 abstract description 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 abstract description 3
- 208000011906 peptic ulcer disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 244000294611 Punica granatum Species 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 238000009835 boiling Methods 0.000 description 27
- 238000001914 filtration Methods 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 230000001376 precipitating effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 206010050953 Lower gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000233948 Typha Species 0.000 description 1
- 244000134857 Typha capensis Species 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009856 intestinal mucosal lesion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
The invention discloses a traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, a preparation method and a preparation thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 7-30 parts of coptis chinensis, 3-15 parts of scutellaria baicalensis, 3-15 parts of sophora flower, 2-10 parts of cacumen biotae, 2-10 parts of schizonepeta, 3-15 parts of fructus aurantii, 2-10 parts of pollen typhae, 7-30 parts of trogopterus dung and 3-15 parts of pomegranate bark; decocting in water to obtain the final product. The traditional Chinese medicine composition provided by the invention is reasonable in compatibility, fills the blank of the field of small intestine mucosa injury treatment of small compound traditional Chinese medicines, relieves small intestine mucosa injury caused by NSAIDs, reduces the occurrence probability of adverse events such as peptic ulcer, gastrointestinal bleeding or perforation caused by NSAIDs, effectively improves the living quality of patients under the combined thought of prevention and treatment, is low in cost, and can be well applied to clinic.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating small intestine mucous membrane injury caused by non-steroidal anti-inflammatory drugs, a preparation method and a preparation thereof.
Background
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, are increasingly used in the analgesic and anti-inflammatory treatment of rheumatic and articular diseases and in the prevention of cardiovascular and cerebrovascular diseases, and adverse events such as peptic ulcers, gastrointestinal bleeding or perforation have become the major complications of these drugs (Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J.Gastrontenol 2008,43(8):581 588.).
With the popularity OF endoscopic and double balloon enteroscopes, researchers have found that NSAIDs-induced small intestinal mucosal lesions account for a significant proportion OF the same (Matsumoto T, Kudo T, Esaki M, et al. Presence OF non-stereo chip J OURNAL OF EVIDENCE-BASED MEDICINE, Apr.2019, Vol.19, No.4anti-inflammatory drug-induced by negative side double-balloon injection, 2008,43(4): 490), and digestive tract hemorrhages have been well documented in humans and animals as common adverse events in NSS (Konaka A, Kato S, Tanakai, Tanakai.517. OF tissue OF animal, U.S. Pat. No. 5. and J. Gastronterol. 2008,43(4): 490), and digestive tract hemorrhages have been well documented in humans and animals as common adverse events in NSals, 2008,57(2): 181-; watanabe T, Nishio H, Tanigawa T, et al, biological Lactobacillus casei strain shibata prevents indexes in-induced small expressed in absolute value of nonvolatile acid, am JPhysiol gateway physiology, 2009,297(3), G506-G513).
Proton Pump Inhibitors (PPIs) are widely used to treat upper gastrointestinal bleeding in patients caused by NSAIDs, but there is increasing evidence that PPIs do not reduce the risk of small intestinal mucosal injury and lower gastrointestinal bleeding (Yamada A, Niikura R, Maki K, et al, Proton pump inhibitor therapy not obtained in advance of small-bowel infusion: apropen-matched assay, PLoS One,2017,12(8): e0182586., Washio E, aki M, Maehata Y, Proton pump infusion therapy not obtained in culture of non-intestinal adhesive infusion pump drug therapy in tissue, Gastron reaction, 2016, 14). However, since the mechanism of the small intestine injury related to NSAIDs is not clear, the application of teprenone to the small intestine related mucosal injury traditionally applied to the gastric mucosa protectant is only reported in sporadic clinical reports (Washio E, Esaki M, Maehata Y, et al, Proton pump inhibition in secretion of non-specific lipid anti-inflammatory drug-induced small bone in vitro: a randomized, plasma-controlled Trial, Clin Gastroenterol Heapatol, 2016,14(6):809 815.), large-scale clinical experiments and animal experiments.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating small intestine mucosal injury caused by non-steroidal anti-inflammatory drugs, a preparation method and a preparation thereof, so as to solve the problems in the prior art and realize effective treatment of the small intestine mucosal injury caused by the non-steroidal anti-inflammatory drugs.
In order to achieve the purpose, the invention provides the following scheme:
one of the technical schemes of the invention is to provide a traditional Chinese medicine composition for treating small intestine mucous membrane injury caused by non-steroidal anti-inflammatory drugs, and the raw materials comprise the following components in parts by weight:
7-30 parts of coptis chinensis, 3-15 parts of scutellaria baicalensis, 3-15 parts of sophora flower, 2-10 parts of cacumen biotae, 2-10 parts of schizonepeta, 3-15 parts of fructus aurantii, 2-10 parts of pollen typhae, 7-30 parts of trogopterus dung and 3-15 parts of pomegranate bark.
Further, the raw materials comprise the following components in parts by weight:
15-30 parts of coptis chinensis, 5-15 parts of scutellaria baicalensis, 5-15 parts of sophora flower, 5-10 parts of cacumen biotae, 5-10 parts of schizonepeta, 5-15 parts of fructus aurantii, 5-10 parts of pollen typhae, 15-30 parts of trogopterus dung and 2-10 parts of pomegranate bark.
The second technical scheme of the invention provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
decocting the raw materials in water according to a ratio, and collecting the filtrate.
Further comprises the process of decocting filter residue and combining the filtrate.
The third technical scheme of the invention provides a traditional Chinese medicine preparation for treating small intestine mucous membrane injury caused by non-steroidal anti-inflammatory drugs, which comprises the traditional Chinese medicine composition with effective treatment amount.
Furthermore, the dosage forms of the traditional Chinese medicine preparation comprise granules, powder, capsules, tablets, mixtures and oral liquid.
The traditional Chinese medicine composition comprises the following components in part by weight:
the composition takes the scutellaria baicalensis and the coptis chinensis as monarch drugs, the coptis chinensis is bitter and cold in nature and enters heart, stomach, liver and large intestine channels, has the functions of clearing heat and drying dampness, and purging fire and removing toxicity, and is a key medicine for clearing heat and removing toxicity.
Cattail pollen and trogopterus dung are ancient prescription powder for removing blood stasis, promoting blood circulation to remove blood stasis, resolving masses to relieve pain, assisting monarch drugs for removing blood stasis and eliminating mass, pungent-flavor for dispersing bitter taste for relieving fever and dredging, not only can break blood and remove stasis, but also can promote qi circulation to relieve pain, schizonepeta is pungent and warm, relieving exterior syndrome and promoting eruption, dispelling wind and regulating blood, are qi-flowing in blood and qi-flowing in blood, and bitter orange for regulating qi-flowing in middle energizer, moving stagnation and relieving distension, are mutually reinforced with cattail pollen and trogopterus dung, and qi-flowing in blood and blood stasis are commonly used as ministerial drugs.
Flos sophorae and cacumen biotae are adjuvant drugs for clearing heat, cooling blood and removing toxicity, the decline of toxic heat can lead to no stagnation of yin blood, the pomegranate rind can astringe intestines and strengthen kidney, astringe essence and stop bleeding, and the blood stasis is dissipated without damaging healthy qi. The prescription takes the ancient classic famous prescription catalog (the first batch) of the Chinese medicinal preparation as the base prescription, and the flos sophorae powder is subjected to reduction and cutting, and all the medicines are combined to play the effects of clearing away heat and toxic materials, removing blood stasis and stopping bleeding.
The invention discloses the following technical effects:
on the basis of the academic idea of treating ulcer diseases by carbuncle, which is provided by the general cultural teaching of physicians and university, the invention aims at the pathogenesis of 'toxin stasis' corresponding to small intestine mucous membrane injury caused by non-steroidal anti-inflammatory drugs, treats the ulcer disease by differentiation of symptoms and signs, preferably selects the raw material medicines and the weight part ratio of the raw material medicines, and the traditional Chinese medicine of the formula accords with the compatibility treatment rule of 'monarch, minister, assistant and guide' and synergistically plays the functions of clearing heat, removing toxicity, removing blood stasis and stopping bleeding.
Clinical results show that the composition has good curative effect due to the weight ratio, fills the blank of the field of small intestine mucosa injury treatment of small compound traditional Chinese medicines, relieves small intestine mucosa injury caused by NSAIDs, reduces the occurrence probability of adverse events such as peptic ulcer, gastrointestinal bleeding or perforation caused by NSAIDs, effectively improves the life quality of patients under the combined idea of prevention and treatment, has low cost, and can be well applied to clinic.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The description and examples are intended to be illustrative only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
The "parts" in the present invention are in parts by weight unless otherwise specified.
The present invention will be further described with reference to the following examples. It should be noted that the Chinese medicinal composition of the present invention can be prepared into granules, powders, capsules, tablets, mixtures or oral liquids, and the like, without affecting the efficacy of the Chinese medicinal composition.
Example 1
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
7 parts of coptis chinensis, 3 parts of scutellaria baicalensis, 3 parts of sophora flower, 2 parts of cacumen biotae, 2 parts of schizonepeta, 3 parts of fructus aurantii, 2 parts of pollen typhae, 7 parts of trogopterus dung and 3 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, and bottling the filtrate I for use;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, and bottling;
(3) mixing the first filtrate and the second filtrate to obtain the decoction of the Chinese medicinal composition.
Example 2
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
30 parts of coptis chinensis, 15 parts of scutellaria baicalensis, 15 parts of sophora flower, 10 parts of cacumen biotae, 10 parts of schizonepeta, 15 parts of fructus aurantii, 10 parts of pollen typhae, 30 parts of trogopterus dung and 15 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, precipitating filtrate I, collecting supernatant, and bottling;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, precipitating filtrate II, collecting supernatant, and bottling;
(3) mixing the two supernatants, heating and concentrating to obtain fluid extract, and granulating to obtain Chinese medicinal granule.
Example 3
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
14 parts of coptis chinensis, 6 parts of scutellaria baicalensis, 6 parts of sophora flower, 4 parts of cacumen biotae, 4 parts of schizonepeta, 6 parts of fructus aurantii, 4 parts of pollen typhae, 14 parts of trogopterus dung and 6 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, precipitating filtrate I, collecting supernatant, and bottling;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, precipitating filtrate II, collecting supernatant, and bottling;
(3) mixing the above supernatants, heating and concentrating to obtain soft extract, adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into tablet.
Pharmaceutical excipients added in this example: the disintegrating agent is dry starch, the wetting agent and the adhesive are starch slurry and dextrin hydroxypropyl methyl cellulose; the addition amount of the pharmaceutical auxiliary materials is the conventional dosage of the traditional Chinese medicine preparation.
Example 4
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
30 parts of coptis chinensis, 15 parts of scutellaria baicalensis, 15 parts of sophora flower, 10 parts of cacumen biotae, 10 parts of schizonepeta, 3 parts of fructus aurantii, 2 parts of pollen typhae, 15 parts of trogopterus dung and 3 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, precipitating filtrate I, collecting supernatant, and bottling;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, precipitating filtrate II, collecting supernatant, and bottling;
(3) mixing the above supernatants, heating, concentrating to obtain soft extract, adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into capsule to obtain capsule.
Pharmaceutical excipients added in this example: the disintegrating agent is dry starch, the wetting agent and the adhesive are starch slurry and dextrin hydroxypropyl methyl cellulose; the addition amount of the pharmaceutical auxiliary materials is the conventional dosage of the traditional Chinese medicine preparation.
Example 5
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
7 parts of coptis chinensis, 15 parts of scutellaria baicalensis, 3 parts of sophora flower, 10 parts of cacumen biotae, 2 parts of schizonepeta, 15 parts of fructus aurantii, 2 parts of pollen typhae, 30 parts of trogopterus dung and 3 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, and bottling the filtrate I for use;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, and bottling;
(3) mixing the first filtrate and the second filtrate to obtain the decoction of the Chinese medicinal composition.
Example 6
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
30 parts of coptis chinensis, 3 parts of scutellaria baicalensis, 15 parts of sophora flower, 2 parts of cacumen biotae, 10 parts of schizonepeta, 3 parts of fructus aurantii, 10 parts of pollen typhae, 7 parts of trogopterus dung and 15 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, precipitating filtrate I, collecting supernatant, and bottling;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, precipitating filtrate II, collecting supernatant, and bottling;
(3) mixing the two supernatants, heating and concentrating to obtain fluid extract, and granulating to obtain Chinese medicinal granule.
Example 7
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
15 parts of coptis chinensis, 15 parts of scutellaria baicalensis, 15 parts of sophora flower, 10 parts of cacumen biotae, 10 parts of schizonepeta, 15 parts of fructus aurantii, 10 parts of pollen typhae, 15 parts of trogopterus dung and 15 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, precipitating filtrate I, collecting supernatant, and bottling;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, precipitating filtrate II, collecting supernatant, and bottling;
(3) mixing the above supernatants, heating and concentrating to obtain soft extract, adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into tablet.
Pharmaceutical excipients added in this example: the disintegrating agent is sodium carboxymethyl starch, the wetting agent and the adhesive are starch slurry and dextrin hydroxypropyl methyl cellulose; the addition amount of the pharmaceutical auxiliary materials is the conventional dosage of the traditional Chinese medicine preparation.
Example 8
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
10 parts of coptis chinensis, 10 parts of scutellaria baicalensis, 10 parts of sophora flower, 10 parts of cacumen biotae, 10 parts of schizonepeta, 10 parts of fructus aurantii, 10 parts of pollen typhae, 10 parts of trogopterus dung and 10 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, precipitating filtrate I, collecting supernatant, and bottling;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, precipitating filtrate II, collecting supernatant, and bottling;
(3) mixing the above supernatants, heating, concentrating to obtain soft extract, adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into capsule to obtain capsule.
Pharmaceutical excipients added in this example: the disintegrating agent is dry starch, the wetting agent and the adhesive are starch slurry and dextrin hydroxypropyl methyl cellulose; the addition amount of the pharmaceutical auxiliary materials is the conventional dosage of the traditional Chinese medicine preparation.
Example 9
A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs comprises the following components in parts by weight:
25 parts of coptis chinensis, 15 parts of scutellaria baicalensis, 10 parts of sophora flower, 10 parts of cacumen biotae, 6 parts of schizonepeta, 9 parts of fructus aurantii, 9 parts of pollen typhae, 10 parts of trogopterus dung and 10 parts of pomegranate bark.
The preparation method comprises the following steps:
(1) taking the raw materials according to the proportion, adding water for decocting, boiling and boiling for 1 hour with soft fire; filtering to obtain filtrate I and residue respectively, and bottling the filtrate I for use;
(2) decocting the obtained medicinal residues in water, boiling with slow fire for 1 hr, filtering to obtain filtrate II, and bottling;
(3) mixing the first filtrate and the second filtrate to obtain the decoction of the Chinese medicinal composition.
The invention is described in further detail below in connection with clinical cases:
1. clinical data:
clinical case research is carried out in outpatient service of traditional Chinese medicine hospitals in Gaoyou city from 12 months to 2020 months in 2018, according to statistics, 35 cases of patients with small intestinal mucosa injury caused by outpatient non-steroidal anti-inflammatory drugs are counted, the age range is 40-86 years, 14 patients take aspirin orally according to acute cerebral infarction disease history rules, 12 patients have rheumatoid arthritis disease history and take non-steroidal anti-inflammatory drugs such as diclofenac sodium orally for a long time, and 9 patients take aspirin according to PCI postoperative rules of coronary atherosclerotic heart disease.
2. Diagnostic criteria:
firstly, no history of peptic ulcer exists in the past; secondly, the history of taking the non-steroidal anti-inflammatory drugs is clear within 1-3 months before the onset of the disease; thirdly, the main clinical symptoms during the treatment are periodic and rhythmic chronic abdominal pain which repeatedly occurs for a long time or limited deep tenderness, acid regurgitation, eructation, nausea, vomiting, bleeding or black stool and the like of the abdomen; and fourthly, the small intestine under the endoscope shows specific mucosal gridding change, and is accompanied with diaphragm stenosis and other non-specific mucosal lesions, including villus loss, mucosal erosion, petechia, ulcer, even active hemorrhage and the like.
3. Clinical case inclusion and elimination criteria
Inclusion criteria were: clinically, the method meets the diagnosis standard of non-steroidal anti-inflammatory drug related small intestinal mucosa injury, except other organic lesions in routine examination, and glucocorticoid and immunosuppressant are not used within 3 months before hospital admission.
Rejection standard: patients with severe organ dysfunction or immune impairment (heart, heart function class IV; chronic hypoxia, obstructive or restrictive ventilatory disturbance, poor exercise tolerance, kidney, chronic dialysis, liver cirrhosis, portal hypertension, hepatic coma, liver failure, immune impairment, receiving radiotherapy, chemotherapy, long-term or massive hormonal therapy such as leukemia, lymphoma, aids, etc.); pregnant and lactating women.
4. Clinical grouping test
After investigation, a total of 12 patients met the clinical trial criteria, ranged in age from 50-82 years, covering three cases in the clinical data section.
The 12 patients were randomly divided into 9 groups, which were designated as experimental groups 1-9, wherein 2 patients were selected from experimental group 2, experimental groups 7 and 8, and 1 patient was selected from the remaining groups.
During the treatment period, the patients of the experimental groups 1 to 9 were administered the Chinese medicinal composition of examples 1 to 9, respectively, wherein: the decoction is administered in 100ml bags for 30 days 2 times per day and 1 bag per time;
granule 6g per bag, and is administered for 30 days 2 times per day and 1 bag per time;
2g tablets, 2 times a day, 3 tablets each time, and 30 days;
capsule, 2g each, is taken 2 times a day, 3 capsules each time, and is taken for 30 days.
The patients with the three types of diseases cannot stop taking the non-steroidal anti-inflammatory drugs, so the oral administration is continued according to the original dose during the treatment period.
5. Determination of therapeutic effect
The curative effect is divided into 3 grades of obvious effect, effective effect and ineffective effect.
The effect is shown: the symptoms of abdominal pain or abdominal localized deep tenderness of the patient completely disappear, and acid regurgitation, belching, nausea, emesis, hematemesis or dark stool do not appear in the treatment period. The mucosa specificity and nonspecific damage under the intestinal endoscope basically disappear, and the mucosa biopsy is also verified.
The method has the following advantages: the symptoms are repeated but can be tolerated, and the mucosa healing ratio is over 50 percent through enteroscopy; or the clinical symptoms have substantially disappeared.
And (4) invalidation: the clinical symptoms are not changed, and the mucosa healing ratio is less than 25 percent through enteroscopy.
The number of patients corresponding to the treatment results of each group is shown in Table 1.
TABLE 1
As can be seen from the table 1, the traditional Chinese medicine composition has an obvious treatment effect on small intestinal mucosa injury caused by the non-steroidal anti-inflammatory drugs, and has a high cure rate.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (6)
1. A traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs is characterized in that raw materials comprise the following components in parts by weight:
7-30 parts of coptis chinensis, 3-15 parts of scutellaria baicalensis, 3-15 parts of sophora flower, 2-10 parts of cacumen biotae, 2-10 parts of schizonepeta, 3-15 parts of fructus aurantii, 2-10 parts of pollen typhae, 7-30 parts of trogopterus dung and 3-15 parts of pomegranate bark.
2. The traditional Chinese medicine composition according to claim 1, wherein the raw materials comprise the following components in parts by weight:
15-30 parts of coptis chinensis, 5-15 parts of scutellaria baicalensis, 5-15 parts of sophora flower, 5-10 parts of cacumen biotae, 5-10 parts of schizonepeta, 5-15 parts of fructus aurantii, 5-10 parts of pollen typhae, 15-30 parts of trogopterus dung and 5-10 parts of pomegranate bark.
3. The method for preparing a Chinese medicinal composition according to any one of claims 1 to 2, comprising the steps of:
decocting the raw materials in water according to a ratio, and collecting the filtrate.
4. The method of claim 3, further comprising the steps of decocting the residue and combining the filtrates.
5. A Chinese medicinal preparation for treating non-steroidal anti-inflammatory drug-induced small intestinal mucosal injury, which comprises a therapeutically effective amount of the Chinese medicinal composition according to any one of claims 1 to 2.
6. The Chinese medicinal preparation as claimed in claim 5, wherein the dosage form of the Chinese medicinal preparation comprises granules, powder, capsules, tablets, mixture and oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111455567.4A CN113908212A (en) | 2021-12-01 | 2021-12-01 | Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111455567.4A CN113908212A (en) | 2021-12-01 | 2021-12-01 | Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113908212A true CN113908212A (en) | 2022-01-11 |
Family
ID=79248553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111455567.4A Pending CN113908212A (en) | 2021-12-01 | 2021-12-01 | Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113908212A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836244A (en) * | 2011-06-21 | 2012-12-26 | 吴同科 | Traditional Chinese medicine sophora japonica powder for treating ulcerative colitis |
-
2021
- 2021-12-01 CN CN202111455567.4A patent/CN113908212A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836244A (en) * | 2011-06-21 | 2012-12-26 | 吴同科 | Traditional Chinese medicine sophora japonica powder for treating ulcerative colitis |
Non-Patent Citations (1)
| Title |
|---|
| 陈莲凤等: "三黄汤灌肠治疗溃疡性结肠炎36例", 《山东中医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110974887A (en) | Traditional Chinese medicine composition for resisting lung cancer | |
| CN111686202A (en) | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof | |
| CN1169561C (en) | Medicine for treating diseases of rectum and anus | |
| CN113908212A (en) | Traditional Chinese medicine composition for treating small intestinal mucosa injury caused by non-steroidal anti-inflammatory drugs, preparation method and preparation thereof | |
| CN101036732A (en) | Chinese medicine preparation for esophagus cancer and its compounding process | |
| CN113648302A (en) | Medicine for treating prostatitis or prostatic hyperplasia | |
| CN110478416B (en) | Composition for treating rheumatic and rheumatoid arthritis and preparation method and application thereof | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN109966442B (en) | Oral and external traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN116370596B (en) | A Chinese medicinal composition for treating biliary tract diseases | |
| CN116370596B9 (en) | A Chinese medicinal composition for treating biliary tract diseases | |
| CN108355124A (en) | A kind of Chinese medicine composition that treating Air way mucus hypersecretion and its application | |
| CN115554374B (en) | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof | |
| CN107233410B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN105998256A (en) | Medicament for treating urinary calculus and preparation method of medicament | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition | |
| CN101028421A (en) | Chinese medicine for treating chronic kidney failure | |
| CN111529640A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for preventing postoperative intestinal polyp recurrence | |
| CN1544058A (en) | Chinese traditional medicine preparation for treating chronic enteritis, colitis and proctitis | |
| CN114903960A (en) | Traditional Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN105233005A (en) | Traditional Chinese medicine composition for preventing infection of skin at catheter opening of central vein indwelling catheter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220111 |